BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24927325)

  • 21. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
    Maeda J; Haskins JS; Kato TA
    Mutat Res; 2023; 826():111815. PubMed ID: 36812659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.
    Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG
    Clin Cancer Res; 2012 Feb; 18(4):1015-27. PubMed ID: 22114138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
    Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
    Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
    Shah MM; Dobbin ZC; Nowsheen S; Wielgos M; Katre AA; Alvarez RD; Konstantinopoulos PA; Yang ES; Landen CN
    Gynecol Oncol; 2014 Aug; 134(2):331-7. PubMed ID: 24844596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
    Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
    J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
    Mukhopadhyay A; Elattar A; Cerbinskaite A; Wilkinson SJ; Drew Y; Kyle S; Los G; Hostomsky Z; Edmondson RJ; Curtin NJ
    Clin Cancer Res; 2010 Apr; 16(8):2344-51. PubMed ID: 20371688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.
    Lee JM; Gordon N; Trepel JB; Lee MJ; Yu M; Kohn EC
    J Transl Med; 2015 Jul; 13():239. PubMed ID: 26198537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.
    Wang Z; Zuo W; Zeng Q; Qian Y; Li Y; Liu C; Wang J; Zhong S; Bu Y; Hu G
    J Biomed Sci; 2019 Feb; 26(1):14. PubMed ID: 30717758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.
    Schultz N; Lopez E; Saleh-Gohari N; Helleday T
    Nucleic Acids Res; 2003 Sep; 31(17):4959-64. PubMed ID: 12930944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
    Jian W; Xu HG; Chen J; Xu ZX; Levitt JM; Stanley JA; Yang ES; Lerner SP; Sonpavde G
    Anticancer Drugs; 2014 Sep; 25(8):878-86. PubMed ID: 24714082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
    Trenner A; Godau J; Sartori AA
    Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
    Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
    BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
    Ying S; Hamdy FC; Helleday T
    Cancer Res; 2012 Jun; 72(11):2814-21. PubMed ID: 22447567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
    Pratz KW; Koh BD; Patel AG; Flatten KS; Poh W; Herman JG; Dilley R; Harrell MI; Smith BD; Karp JE; Swisher EM; McDevitt MA; Kaufmann SH
    Clin Cancer Res; 2016 Aug; 22(15):3894-902. PubMed ID: 26979391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
    Cao P; Wang Y; Lv Y; Jiang N; Zhong L; Ma X; Xiao X; Ding D; Gu J; Lin L; Li S
    Oncol Rep; 2019 Nov; 42(5):2097-2107. PubMed ID: 31545455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9‑induced saturated mutagenesis identifies
    Yang H; Wei Y; Zhang Q; Yang Y; Bi X; Yang L; Xiao N; Zang A; Ren L; Li X
    Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35713220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
    de Jonge MM; Auguste A; van Wijk LM; Schouten PC; Meijers M; Ter Haar NT; Smit VTHBM; Nout RA; Glaire MA; Church DN; Vrieling H; Job B; Boursin Y; de Kroon CD; Rouleau E; Leary A; Vreeswijk MPG; Bosse T
    Clin Cancer Res; 2019 Feb; 25(3):1087-1097. PubMed ID: 30413523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
    Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
    Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
    Moudry P; Watanabe K; Wolanin KM; Bartkova J; Wassing IE; Watanabe S; Strauss R; Troelsgaard Pedersen R; Oestergaard VH; Lisby M; Andújar-Sánchez M; Maya-Mendoza A; Esashi F; Lukas J; Bartek J
    J Cell Biol; 2016 Feb; 212(3):281-8. PubMed ID: 26811421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.